Glutamic Acid

Glutamic Acid

SCHEMBL4607705

N[C@@H](CCC(=O)O)C(=O)O.[GaH3]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 2/20 0.95
GRM6 O15303 2/20 0.95
GRM7 Q14831 2/20 0.95
GRM4 Q14833 2/20 0.95
GSR P00390 2/20 0.95
GRIN2D O15399 1/20 0.95
GRIN3B O60391 1/20 0.95
CYP1A2 P05177 1/20 0.95
GRIK1 P39086 1/20 0.95
GRM5 P41594 1/20 0.95
GRIA1 P42261 1/20 0.95
GRIA2 P42262 1/20 0.95
GRIA3 P42263 1/20 0.95
SLC1A3 P43003 1/20 0.95
SLC1A2 P43004 1/20 0.95
SLC1A1 P43005 1/20 0.95
GRIA4 P48058 1/20 0.95
GRIN1 Q05586 1/20 0.95
GRIN2A Q12879 1/20 0.95
GRIK2 Q13002 1/20 0.95

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL27762710 1.00 GRM8 (0.95) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL1332297 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL1330824 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL410241 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL248800 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL1554237 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL5704264 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL1330484 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL17127348 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL2201 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101374532-A Use of gallium for treating biofilm-associated infections TITAN PHARMACEUTICALS INC (US) 2009-02-25 CN disclosed
CN-101300033-A Treatment and prevention of adverse liver conditions using gallium TITAN PHARMACEUTICALS INC (US) 2008-11-05 CN disclosed
EP-1978976-A2 USE OF GALLIUM TO TREAT BIOFILM-ASSOCIATED INFECTONS TITAN PHARMACEUTICALS, INC. (US) 2008-10-15 EP disclosed
EP-1945273-A1 TREATMENT AND PREVENTION OF ADVERSE LIVER CONDITIONS USING GALLIUM TITAN PHARMACEUTICALS, INC. (US) 2008-07-23 EP disclosed
US-20070231406-A1 Use of gallium to treat biofilm-associated infections TITAN PHARMACEUTICALS, INC. 2007-10-04 US disclosed
US-20070231407-A1 Method of treating gallium-nitrate resistant tumors using gallium-containing compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-10-04 US disclosed
WO-2007087461-A2 USE OF GALLIUM TO TREAT BIOFILM-ASSOCIATED INFECTONS TITAN PHARMACEUTICALS, INC. (US) 2007-08-02 WO disclosed
US-20070128294-A1 Treatment and prevention of liver adverse conditions using gallium TITAN PHARMACEUTICALS, INC. 2007-06-07 US disclosed
WO-2007056440-A1 TREATMENT AND PREVENTION OF ADVERSE LIVER CONDITIONS USING GALLIUM TITAN PHARMACEUTICALS, INC. (US) 2007-05-18 WO disclosed